Navigation Links
MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities
Date:3/5/2010

ATLANTA, March 5 /PRNewswire/ -- MedShape Solutions announced today that it is pursuing Phase III SBIR awards and has received preferred vendor status at Veterans Health Administration Hospitals and other Federally funded hospitals for its MORPHIX ™ Shape Memory Suture Anchor.  The MORPHIX device was developed with financial assistance through NIH/NIAMS Grants # 1R43AR056154-01, 2R44AR056154-02, 5R44AR056154-03.  The MORPHIX Anchor is being highlighted and launched nationally at the American Academy of Orthopedic Surgeons meeting in New Orleans, March 10-13, 2010.

The Small Business Act Policy Directive provides that "Government owned, contractor operated facilities….give preference including sole source awards to the awardee that developed the technology."  Section 4 (c) (7)  The Directive also states that "the competition for SBIR Phase I and Phase II awards satisfies any competition requirement of the Armed Services Procurement Act, The Federal Property and Administrative Services Act and the Competition in Contracting Act."  Section 4 (c) (3)

"The development of the MORPHIX Suture Anchor with SBIR support was a textbook case of how a partnership in development should occur.  The grant funding received was critical to the development success and eventual commercialization of this innovative technology," stated Chris Fair, Chief Operations Officer of MedShape Solutions.

MedShape Solutions initial product is the MORPHIX Suture Anchor made from proprietary shape memory PEEK Altera.   "We anticipate releasing additional technologies in the months ahead that were  supported via SBIR Phase I & Phase II awards for their development.  These technologies will also receive the same preferred supplier status within their product category," stated Kurt Jacobus, PhD, President & CEO of MedShape Solutions.

MedShape Solutions is a privately held company focused on developing orthopedic devices from proprietary shape memory technology.  You may find more information at www.medshape.com.

If you are a government purchasing group and would like additional information, please contact Chris Fair, Chief Operating Officer of MedShape Solutions at (404) 249-9155 or send an email to gov@medshape.com .

SOURCE MedShape Solutions, Inc.

Back to top

RELATED LINKS
http://www.medshape.com

'/>"/>

SOURCE MedShape Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MedShape Solutions, Inc. Announces First FDA-cleared Shape Memory PEEK Device; Closing of $10M Equity Offering
2. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
3. NexInfo Solutions, Inc. Selected by Beckman Coulter to Design and Streamline Global Sales & Operations Planning Processes
4. Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
5. Jovianna DiCarlo Named ConsentSolutions, Inc. President & Chief Executive Officer
6. Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
7. Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership
8. Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister
9. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
10. Premier Research Group plc and Octagon Research Solutions, Inc. Announce Strategic Partnership
11. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
Breaking Biology News(10 mins):